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Abstract
Background: Annual chlamydia (CT) screening is recommended for women younger than 25 
years, yet less than half of young women seeking health care are screened annually. We analyzed 
Title X family planning service data from the Northwest United States to assess factors associated 
with missed opportunities for CT screening. Our primary hypothesis was screening coverage is 
higher during annual preventive health visits compared to other visit types. Study objectives were: 
(1) identify gaps in screening coverage by patient demographics, visit characteristics, and clinic 
measures; and (2) examine the association between visit type and CT screening by controlling for 
other covariates and stratifying by state.
Methods: Calendar year 2011 Title X visit records (n = 180,856) were aggregated to the patient 
level (n = 112,926) to assess CT screening coverage by all characteristics. Screening variation was 
explored by bivariate and multivariate Poisson regression. Adjusted models for each state 
estimated association between comprehensive examination and screening controlling for 
confounders.
Results: Clinic and visit characteristics were associated with CT screening. Coverage ranged 
from 45% in Washington to 80% in Alaska. Only 34% of patients visited for a routine 
comprehensive examination. Visit type was associated with screening; 75% of patients who had a 
comprehensive examination were screened versus 34% of those without a comprehensive 
examination (unadjusted PR, 2.18; 95% confidence interval, 2.16–2.21). The association between 
comprehensive examination and CT screening varied significantly by state (interaction term, P < 
0.001).
Conclusions: Missed screening opportunities are common among women who access brief 
appointments for specific needs but do not seek routine preventive care, particularly in some states. 
Structural interventions may help address these systematically missed opportunities.
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Young women are at high risk of Chlamydia trachomatis (CT) infection. Serious health 
consequences of untreated CT include pelvic inflammatory disease, ectopic pregnancy, and 
infertility.1 Because this sexually transmitted infection (STI) is often asymptomatic, annual 
screening for women younger than 25 years is necessary to identify and treat most 
infections.1,2 In practice, however, less than half of sexually active young women seeking 
health care are screened each year.3,4 Title X family planning (FP) clinics are major 
providers of reproductive health care for young women, including STI screening. Despite 
their reproductive health focus, only 58% of women aged 25 years or younger in Title X-
funded FP clinics were screened in 2011, and screening coverage has plateaued in recent 
years.5,6
Successful interventions to improve CT screening coverage in FP, and other clinic types 
have included development and dissemination of national screening guidelines and 
performance measures, quality improvement initiatives involving data review and feedback 
to clinicians, laboratory requisition form modifications, required documentation of reason 
for screening, and changes to clinical protocols, for example, placing CT specimen 
collection kits alongside Pap test materials.4,7–9 Additionally, technological innovations, 
such as self-collected vaginal swabs, mail-in test kits, and patient and provider reminder 
systems, have improved screening.10–13
Despite these advances, experts hypothesize that large-scale structural barriers may be 
contributing to low screening coverage, including limited resources to support screening and 
unrealistic demands on clinician time.14,15 Screening coverage varies by health plan 
(commercial vs Medicaid plans), as well as by provider characteristics including Title X 
participation, patient volume, public versus private sites, patient volume, percent urban/rural 
location, and percent African American patients.3,16 Exploring variation in screening at 
multiple levels (ie, across states and amongst patients) may uncover missed opportunities for 
testing and inform future interventions to improve screening coverage.
Our study used secondary analysis of Title X patient FP service data to assess factors 
associated with missed opportunities for CT screening among female patients aged 15 to 24 
years. Our primary hypothesis was that screening coverage is higher during annual 
preventive health visits compared with other visit types, and our secondary hypothesis was 
that this relationship may vary by state. Our study objectives were (1) identify gaps in 
screening coverage by patient demographics, visit characteristics, and clinic measures; and 
(2) examine the association between visit type and CT screening by controlling for other 
covariates and stratifying by state, if state is determined to be an effect modifier.
MATERIALS AND METHODS
Data Sources
This study used data from US Public Health Service Region X’s (Washington, Idaho, 
Oregon, and Alaska) Title X program from calendar year 2011 (CY2011). This data set 
contained patient demographic information (sex, age, races, and ethnicity), and visit 
characteristics (type of visit, insurance status, number of visits, and whether a CT test was 
performed). We also integrated 2 clinic measures from clinic lists maintained for data 
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management: the state in which the clinic was located, and whether the clinic participated in 
the national Infertility Prevention Project (IPP), a public sector STI screening and treatment 
program. Though these programs maintained distinct data reporting systems, over 70% of 
Region X Title X–funded clinics participated in IPP.
Title X FP Database—The database contained encounter (visit) records that FP agencies 
extracted from their administrative information systems and reported to a regional data 
processor. The data processor compiled and sent annual data files to Cardea Services, the 
Region X Title X data manager for management, analysis, and submission to the federal 
Office of Population Affairs (OPA).
Records contained clinic and patient identifiers, demographics, and visit characteristics. 
Demographics included sex, age, race(s), and ethnicity. Visit characteristics included visit 
type (initial medical examination, annual medical examination, positive laboratory test 
follow-up, counseling-only visits, contraceptive method, or pregnancy-test only visit), 
clinical services (eg, blood pressure, breast examination, bimanual pelvic, and so on), 
insurance, and laboratory tests ordered (eg, Pap, CT, gonorrhea, syphilis, and human 
immunodeficiency virus), and contraception, counseling, and referral services.17
During data collection, patients’ principal insurance was documented as “private,” “public” 
(defined as either “Medicaid or Medicare”), “uninsured,” or “unknown.” In accordance with 
OPA guidelines, insurance through Medicaid FP expansion programs was documented 
differently depending on services provided. Family planning expansion programs covering a 
broad set of primary care benefits—including FP—were documented as “public insurance,” 
whereas those only covering FP services, but excluding broader primary care, were 
documented as “uninsured.”
Title X—IPP Clinic List—The Title X—IPP clinic list database was developed by Cardea 
staff for data management purposes, as Cardea served as data manager for both the Title X 
and IPP programs. The database contained a list of clinics participating in the Title X and 
IPP programs and established a common unique identifier for each clinic.
Data Management and Statistical Analyses
The Title X data set contained 180,856 encounter records from female patients aged 15 to 24 
years, CY2011. Region X IPP guidelines recommended annual CT screening for females 
aged 24 years or younger. We aggregated Title X visit records to patient level (n = 112,926) 
to estimate annual screening coverage (number of women tested for CT at least once in the 
calendar year/number of women accessing services in the calendar year). Measures in the 
aggregate data set included clinic ID, patient ID, date of birth, age at most recent visit, race/
ethnicity, insurance type, number of CY2011 clinic visits, visit types, and any CT test during 
CY2011 (dichotomous yes/no). Clinic IPP participation and state where clinic was located 
was merged from clinic lists.
When aggregating to the patient level, a binary variable was created from visit type to 
indicate whether or not the patient had any preventive health visit at any point during the 
year. The resulting variable in the aggregate data set was called “comprehensive 
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examination.” Visits were considered comprehensive if they included blood pressure, height/
weight, thyroid examination, heart and lung auscultation, breast examination, abdominal 
palpation, extremities, bimanual/speculum pelvic examination, and appropriate laboratory 
services.17
Item frequency distributions were generated; cross-tabulations were computed for CT 
screening. To investigate our hypothesis for an association between visit type and screening, 
we used Poisson regression to determine bivariate and multivariate prevalence ratios and 
95% confidence intervals (CIs) for CT screening. Effect modification was assessed by 
including an interaction term for visit type by state. Because the interaction term was 
significant, we constructed separate multivariate models for each state and assessed 
confounding for each model using a 10% change-in-estimate approach for covariates 
significant at the bivariate level. Given the large sample size, P values <0.001 were 
considered statistically significant for all statistical tests. Analyses were conducted using 
SPSS version 19. Data were collected as part of routine surveillance activities related to FP 
service provision and sexually transmitted disease control among women. All data used for 
analysis were deidentified. Centers for Disease Control and Prevention determined this 
project was nonresearch.
RESULTS
In 2011, Region X Title X clinics served 112,926 female patients aged 15 to 24 years (Table 
1). Median age was 20 years; 70% were non-Hispanic (NH) white, 16% Hispanic, and all 
other racial groups ≤3%. Over half (52%) were uninsured. Almost two thirds (66%) visited 
the clinic only once, and 34% had a comprehensive examination. About half (48%, n = 
54,325) were tested for CT at least once during 2011.
Screening coverage varied significantly by patient demographics, but absolute differences 
were modest (Table 2). Coverage was highest among women aged 20 to 24 years, American 
Indian/Alaska Native, and NH white patients. Coverage was substantially higher in Alaska 
(80%) and Idaho (62%) compared with Oregon (46%) and Washington (45%). Publicly 
insured patients were significantly less likely to be screened than privately insured or 
uninsured patients (39% compared with 52% and 50%, respectively). Screening was 
associated with number of clinic visits (67% screened among patients that visited 3 or more 
times compared with 41% of patients that visited only once) and was modestly higher in IPP 
clinics (50% IPP vs 43% non-IPP clinics). Comprehensive examination was associated with 
screening; 75% of patients who had a comprehensive examination were screened versus 
34% of those without a comprehensive examination during 2011 (unadjusted PR, 2.18; 95% 
CI, 2.16–2.21).
The prevalence of a comprehensive examination varied by state (Alaska, 21%; Idaho, 60%; 
Oregon, 30%; Washington, 34%). The association between comprehensive examination and 
CT screening also varied by state (interaction term, P < 0.001) (Table 3). In Washington’s 
adjusted model, age, race/ethnicity, state, number of clinic visits, and clinic participation in 
IPP confounded the association between comprehensive examination and CT screening by 
greater than 10%. In the remaining states, none of the factors explored confounded the effect 
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of comprehensive examination on CT screening, so unadjusted PRs were used. In Idaho, the 
prevalence of screening at a comprehensive examination was nearly 4 times the prevalence 
of screening at other visit types, whereas in Alaska, screening coverage was about the same 
regardless of visit type.
DISCUSSION
This analysis used a large regional administrative information database to explore missed 
opportunities for CT screening from a multilevel perspective that considered characteristics 
of individual patients as well as the systems in which they sought care. Clinic and visit 
characteristics (state and visit type, followed by type of insurance and number of clinic 
visits) were predictive of CT screening, whereas patient demographics were not.
Overall, patients were more than twice as likely to be screened for CT if they had a 
comprehensive examination during the year. This finding likely reflects clinical protocols 
that only include routine CT screening during annual preventive care visits. Most clinical 
interventions to increase CT screening have deliberately tied it to other preventive health 
services, such as cervical cytology screening.9,18 Although these interventions did increase 
screening coverage, our finding that only 45% of patients visited the clinic for a 
comprehensive examination (when, by definition, most preventive health services should be 
provided) suggests that linking CT screening to cervical cytology screening is inherently 
problematic. Other recent research revealed additional reasons why this linkage is 
problematic. Moyer observed that a recent change in federal guidance reducing the 
recommended frequency of cervical cytology screening unintentionally lead to a reduction 
in CT screening coverage.19 Thus, interventions that dissociate CT screenings from other 
preventive health services may warrant exploration.
An alternative option for a CT screening protocol could include adding a flag or pop up to 
electronic health records to screen women the first time they visit each calendar year 
regardless of visit type rather than waiting for their annual preventive care examination. To 
be successful, such a protocol would require appropriate resources and system changes, for 
example, providing vaginal swab self-collection kits during intake and issuing standing 
orders enabling midlevel practitioners to order CT tests.15,20,21
The large differences we observed in screening coverage by state have been documented in 
federal Title X reports.5 Our results expanded the scope of this issue by examining states’ 
variation in screening by visit type. In 3 of 4 states, patients who had received 
comprehensive examinations were consistently screened for CT (81.8%–88.7%). However, 
most visits did not involve a comprehensive examination and likelihood of screening during 
other visit types varied considerably among states, even after adjusting for observed 
confounders.
Further research is needed to better explain whether observed differences in CT screening by 
state reflect state-level policy differences and/or variation among the constellations of 
individual programs, agencies, clinics, and providers operating within each state. 
Differences in reimbursement policies for CT tests among Medicaid waiver programs, state 
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funds allocated for CT testing, and the size and level of centralization of the state FP 
program could cause differences in screening by state. However, variation in clinical 
protocols and practices among programs, agencies, clinics, and individual providers within 
states could also explain our findings. A recent study found Region X Title X clinic 
screening coverage ranged from 11–92%.22 Additionally, Chow et al16 found that screening 
coverage among women aged 25 years or younger was higher among Title X providers than 
non–Title X public and private providers in California.
Not surprisingly, screening increased with number of clinic visits, as higher-risk patients and 
patients diagnosed with STIs may visit more frequently for follow up. Additionally, the 
more frequently a patient visits the clinic, the greater the number of opportunities her 
provider has had to screen her. Nevertheless, our results showed that one third of patients 
visiting 3 or more times were never screened for CT, which underscores the need to address 
missed screening opportunities.
Lastly, we were surprised to find that publicly insured patients were least likely to be 
screened. Others have documented CT screening differences by insurance. The National 
Committee for Quality Assurance consistently reports higher screening coverage in 
Medicaid compared to commercial plans.3 Pourat et al23 reported higher screening coverage 
among publicly insured versus uninsured individuals, though this was based on a self-report 
survey of the general population. One possible explanation for our finding is that clinical 
screening protocols were developed to align with billing and reimbursement opportunities 
that may vary by patient mix and state Medicaid waivers. Because some states have 
implemented Medicaid expansion under the Affordable Care Act whereas others have not, 
assessing the impact of billing and reimbursement opportunities on CT screening coverage 
will remain important.24
Our study had a number of limitations. First, our data came from an administrative database 
where CT screening may be underreported.25 It is possible that underreporting could differ 
by visit type or other visit characteristics, though it is unlikely to eliminate the large 
difference we observed in screening coverage by visit type. Second, we did not have a 
measure to remove nonsexually active patients, though the percentage is likely small in FP 
clinics. Third, Region X results are not generalizable nationwide. Fourth, visits covered by 
the Medicaid Expansion program for FP-only services were documented as “uninsured” in 
the regional database during data collection. Thus, there was no way for the authors to assess 
the volume of visits covered by the Medicaid Expansion program or to explore this group 
separately from patients whose visits were not covered by any type of insurance. Fifth, the 
data used for this analysis are from 2011 (the latest year for which visit- or patient-level data 
were available), and it is possible that screening practices could have changed as a result of 
improved insurance coverage or declined due to the ending of the IPP program which 
focused particular attention on CT screening for young women. Although patient-level data 
are not available later than 2011, aggregate screening coverage data presented in more recent 
Family Planning Annual Reports published by OPA indicates crude screening coverage rates 
have been stable, 2011 through 2015. Additionally, the 10 federal regions have maintained 
the same administrative functions, and programmatic guidelines for Title X clinics regarding 
CT screening have remained consistent. Finally, we caution readers not to interpret our 
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univariate results as total effect estimates for each covariate, because these were exploratory 
analyses not informed by causal models.26 Our interest was comparing approximate 
strengths of associations across covariates, not precisely estimating each association.
This study has several strengths. First, although there is a significant amount of national, 
regional, and state data on crude screening coverage rates over time, this has not been 
examined at a more granular level. The Region X data set included a robust set of covariates 
that enabled a more detailed exploration of screening coverage. Our study revealed very 
large differences in service provision in some states, which has significant programmatic 
implications for how clinical interventions could be designed to maximize screening.
After 25 years of national efforts to increase CT screening coverage, screening coverage 
among women aged 24 years and younger remains suboptimal. This study suggests that 
multiple factors contribute to low screening coverage in FP clinics. Most significantly, we 
found that the majority of missed screening opportunities occur among patients who seek 
care for specific needs but do not receive routine preventive care, and that these patients 
constitute more than half of the Title X patient population. We also found that this 
differential in screening coverage varied significantly by state, suggesting that there may be 
more complex factors underlying this association. Further research is needed to understand 
whether structural interventions that dissociate CT screening from visit type could increase 
screening coverage across all visit types. Looking at policies and procedures in Alaska 
where screening coverage is high across all visit types could identify replicable models. 
However, additional structural interventions may also be needed to address larger system 
and policy issues such as insurer reimbursement that may create barriers to screening.
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TABLE 1.
Distribution of Characteristics Within Study Sample (n = 112,926)
Characteristic n % of Sample
Demographics
 Age, y
  15–17 20,413 18.1
  18–19 25,772 22.8
  20–24 66,741 59.1
 Race/ethnicity
  NH White 79,745 70.6
  NH Black 3021 2.7
  American Indian/Alaskan Native 1682 1.5
  Asian 3442 3.0
  Native Hawaiian/Other Pacific Islander 880 0.8
  Hispanic 18,281 16.2
  Other, >1 race, or missing* 5875 5.2
Visit characteristics
 Insurance Status
  Public 21,058 18.6
  Private 18,371 16.3
  Uninsured 59,156 52.4
  Unknown/missing 14,341 12.7
 No. clinic visits
  1 74,350 65.8
  2 22,124 19.6
  3+ 16,452 14.6
 CE
  No 74,213 65.7
  Yes 38,713 34.3
 CT test done
  No 58,601 51.9
  Yes 54,325 48.1
Clinic measures
 State
  Alaska 3970 3.5
  Idaho 10,594 9.4
  Oregon 56,916 50.4
  Washington 41,446 36.7
 Participates in IPP
  No 23,715 21.0
  Yes 89,211 79.0
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*
Included 2362 (2.1%) patients that reported “other race,” 99 (0.1%) that reported more than 1 nonwhite race, and 3414 (3.0 %) with unknown/
missing race.
CE, comprehensive examination.
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